Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

Connection

Robert Weinstein to Osteoporosis

This is a "connection" page, showing publications Robert Weinstein has written about Osteoporosis.

 
Connection Strength
 
 
 
1.818
 
  1. Weinstein RS. Glucocorticoid-induced osteoporosis and osteonecrosis. Endocrinol Metab Clin North Am. 2012 Sep; 41(3):595-611.
    View in: PubMed
    Score: 0.372
  2. Weinstein RS. Clinical practice. Glucocorticoid-induced bone disease. N Engl J Med. 2011 Jul 07; 365(1):62-70.
    View in: PubMed
    Score: 0.350
  3. Orwoll ES, Miller PD, Adachi JD, Brown J, Adler RA, Kendler D, Bucci-Rechtweg C, Readie A, Mesenbrink P, Weinstein RS. Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5?mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study. J Bone Miner Res. 2010 Oct; 25(10):2239-50.
    View in: PubMed
    Score: 0.332
  4. Jain N, Weinstein RS. Giant osteoclasts after long-term bisphosphonate therapy: diagnostic challenges. Nat Rev Rheumatol. 2009 Jun; 5(6):341-6.
    View in: PubMed
    Score: 0.303
  5. Weinstein RS, Jia D, Powers CC, Stewart SA, Jilka RL, Parfitt AM, Manolagas SC. The skeletal effects of glucocorticoid excess override those of orchidectomy in mice. Endocrinology. 2004 Apr; 145(4):1980-7.
    View in: PubMed
    Score: 0.208
  6. Ambrogini E, Que X, Wang S, Yamaguchi F, Weinstein RS, Tsimikas S, Manolagas SC, Witztum JL, Jilka RL. Oxidation-specific epitopes restrain bone formation. Nat Commun. 2018 06 06; 9(1):2193.
    View in: PubMed
    Score: 0.141
  7. Weinstein RS. Glucocorticoids, osteocytes, and skeletal fragility: the role of bone vascularity. Bone. 2010 Mar; 46(3):564-70.
    View in: PubMed
    Score: 0.076
  8. Martin-Millan M, Almeida M, Ambrogini E, Han L, Zhao H, Weinstein RS, Jilka RL, O'Brien CA, Manolagas SC. The estrogen receptor-alpha in osteoclasts mediates the protective effects of estrogens on cancellous but not cortical bone. Mol Endocrinol. 2010 Feb; 24(2):323-34.
    View in: PubMed
    Score: 0.020
  9. Ali AA, Weinstein RS, Stewart SA, Parfitt AM, Manolagas SC, Jilka RL. Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology. 2005 Mar; 146(3):1226-35.
    View in: PubMed
    Score: 0.014
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.